乙基4-(4-甲氧基苯基)-2,4-二氧代丁酸酯 | 35322-20-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 乙基4-(4-甲氧基苯基)-2,4-二氧代丁酸酯
• 中文别名: 乙基4-甲氧基-A,G-二氧代-苯丁酸酯；4-甲氧基-A,G-二氧代-苯丁酸乙酯
• 英文名称: ethyl 3-(4-methoxybenzoyl)pyruvate
• 英文别名: ethyl 4-(4-methoxyphenyl)-2,4-dioxobutanoate；ethyl 2,4-dioxo-4-(4-methoxyphenyl)butanoate
• CAS: 35322-20-4
• 化学式: C₁₃H₁₄O₅
• mdl: MFCD01165877
• 分子量: 250.251
• InChiKey: JHWYUCIVJQZDEF-UHFFFAOYSA-N

物化性质

• 熔点：
  52-57 °C
• 沸点：
  407.0±25.0 °C(Predicted)
• 密度：
  1.182±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2918990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 4-(4-methoxyphenyl)-2,4-dioxobutanoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 4-(4-methoxyphenyl)-2,4-dioxobutanoate
CAS number: 35322-20-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H14O5
Molecular weight: 250.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  乙基4-(4-甲氧基苯基)-2,4-二氧代丁酸酯 在 溶剂黄146 、 lithium hydroxide 、 肼 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 5-(4-甲氧基苯基)-1H-吡唑-3-羧酸
  参考文献：
  名称：

  某些新型3-苯基-N- [3-（4-苯基哌嗪-1基）丙基] -1 H-吡唑-5-羧酰胺衍生物的合成及抗炎活性

  摘要：

  合成了一系列新的3-苯基-N- [3-（4-苯基哌嗪-1基）丙基] -1H-吡唑-5-羧酰胺衍生物，并用角叉菜胶诱导的大鼠爪水肿模型研究了它们的抗炎活性。体内。发现所有合成的化合物都是有效的抗炎药。

  DOI：

  10.1016/j.bmcl.2011.05.105
• 作为产物：
  描述：

  4-甲氧基苯甲醛 在 manganese(IV) oxide 、 silica gel 、 sodium hydride 作用下， 以 四氢呋喃 、 甲苯 、 乙腈 为溶剂， 反应 13.17h， 生成 乙基4-(4-甲氧基苯基)-2,4-二氧代丁酸酯
  参考文献：
  名称：

  FtsZ调节剂的新型含异恶唑的苯甲酰胺衍生物的设计，合成和基于结构的优化

  摘要：

  临床上重要的细菌病原体中的抗生素耐药性正成为对公共卫生的普遍威胁，因此迫切需要具有新颖作用机制的新型抗菌剂。利用计算对接方法和基于结构的优化策略，我们合理地设计和合成了针对细菌细胞分裂蛋白FtsZ的两个系列的含异恶唑-3-基和异恶唑-5-基的苯甲酰胺衍生物。评估它们对一组革兰氏阳性和阴性病原体的活性表明，具有异恶唑-5-基的化合物B14和B16对包括耐甲氧西林的金黄色葡萄球菌在内的各种测试菌株均显示出强大的抗菌活性。和耐青霉素的金黄色葡萄球菌。进一步的分子生物学研究和对接分析证明，该化合物可作为有效抑制剂，通过刺激机制改变FtsZ自聚合动力学，最终终止细胞分裂并导致细胞死亡。综上所述，这些结果可能暗示了开发新型靶向FtsZ的杀菌剂的有希望的化学型。

  DOI：

  10.1016/j.ejmech.2018.09.053

文献信息

• Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents
  作者：Burcu Çalışkan、Esra Sinoplu、Kübra İbiş、Ece Akhan Güzelcan、Rengül Çetin Atalay、Erden Banoglu

  DOI：10.1080/14756366.2018.1504041

  日期：2018.1.1

  In our endeavour towards the development of effective anticancer therapeutics, a novel series of isoxazole-piperazine hybrids were synthesized and evaluated for their cytotoxic activities against human liver (Huh7 and Mahlavu) and breast (MCF-7) cancer cell lines. Within series, compounds 5l-o showed the most potent cytotoxicity on all cell lines with IC50 values in the range of 0.3-3.7 μM. To explore

  在我们努力开发有效的抗癌疗法的过程中，合成了一系列新的异恶唑-哌嗪杂种，并评估了它们对人肝（Huh7和Mahlavu）和乳腺癌（MCF-7）癌细胞系的细胞毒活性。在系列中，化合物5l-o在所有细胞系中显示出最强的细胞毒性，IC50值在0.3-3.7μM的范围内。为了探究观察到的活性的基本机制，对肝癌细胞中5m和5o进行了进一步的生物学研究。我们已经证明5m和5o在足够的PTEN Huh7和PTEN不足的Mahlavu人肝癌细胞中诱导氧化应激，导致细胞凋亡和细胞周期停滞在不同阶段。
• Pyridopyridazine compounds and their use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05420275A1

  公开（公告）日：1995-05-30

  An assay method which comprises utilizing chemiluminescence of a pyridopyridazine compound of the formula ##STR1## wherein R.sub.1 is a hydrocarbon group or a heterocyclic group each of which may be substituted and R.sub.2 is hydroxy group, thiol group, amino group or a monosubstituted amino group, and when R.sub.2 is a monosubstituted amino group, R.sub.2 may be taken together with R.sub.1 to form the ring; R.sub.3 is hydrogen atom, a hydroxy group which may be substituted, an amino group which may be substituted, a thiol group which may be substituted, a halogen atom, a heterocyclic group, nitro group, cyano group, carboxyl group which may be esterified or amidated, azido group, sulfo group or an organic sulfonyl group, provided that when R.sub.1 is an aliphalic group, R.sub.3 is not hydrogen atom; and X is oxygen atom or sulfur atom/or a salt thereof; and a novel compound of the formula (I) wherein the symbols are as defined above with proviso that R.sub.3 is hydrogen atom, R.sub.1 is a substituted aryl group or a heterocyclic group which may be substituted, or a salt thereof and the production methods thereof.

  一种测定方法，包括利用式中的吡啶吡啶二氮化合物的化学发光##STR1##，其中R.sub.1是一个烃基或杂环基，每个基可能被取代，R.sub.2是羟基、硫醇基、氨基或单取代氨基，当R.sub.2是单取代氨基时，R.sub.2可以与R.sub.1一起形成环；R.sub.3是氢原子、可能被取代的羟基、可能被取代的氨基、可能被取代的硫醇基、卤素原子、杂环基、硝基、氰基、可能被酯化或酰胺化的羧基、叠氮基、磺酰基或有机磺酰基，但当R.sub.1是脂肪族基时，R.sub.3不是氢原子；X是氧原子或硫原子/或其盐；以及式(I)的新化合物，其中符号如上所定义，但R.sub.3是氢原子，R.sub.1是取代芳基或可能被取代的杂环基，或其盐以及其生产方法。
• An Optimised Small-Molecule Stabiliser of the 14-3-3-PMA2 Protein-Protein Interaction
  作者：Anja Richter、Rolf Rose、Christian Hedberg、Herbert Waldmann、Christian Ottmann

  DOI：10.1002/chem.201103761

  日期：2012.5.21

  Modulation of protein–protein interactions (PPIs) is a highly demanding, but also a very promising approach in chemical biology and targeted drug discovery. In contrast to inhibiting PPIs with small, chemically tractable molecules, stabilisation of these interactions can only be achieved with complex natural products, like rapamycin, FK506, taxol, forskolin, brefeldin and fusicoccin. Fusicoccin stabilises

  蛋白质间相互作用（PPI）的调节在化学生物学和靶向药物发现中是非常需要的，但也是非常有前途的方法。与使用化学上易处理的小分子抑制PPI相比，只有通过复杂的天然产物（如雷帕霉素，FK506，紫杉醇，福司可林，布雷菲德丁和富西花青素）才能实现这些相互作用的稳定化。Fusicoccin可稳定植物H + -ATPase PMA2和14-3-3蛋白的活化复合物。最近，我们已经表明，fusicoccin的稳定作用可以通过三取代的吡咯啉酮（pyrrolidone1，来模拟1）。在这里，我们报告1的衍生物的合成，功能活性和晶体结构可以稳定14-3-3-PMA2复合物。通过有限的化合物收集，可以确定对于活性增强而言很重要的三个修饰：1）吡咯烷酮支架向吡唑的转化； 2）将四唑部分引入与PMA2接触的苯环，以及3）添加溴与仅与14-3-3蛋白接触的苯环相连。1的吡唑衍生物与14-3-3和PMA2形成复合物的晶体
• [EN] AZAINDAZOLES<br/>[FR] AZAINDAZOLES
  申请人：GLAX0SMITHKLINE LLC

  公开号：WO2013039988A1

  公开（公告）日：2013-03-21

  Herein are disclosed azaindazoles of formula (I), (I), where the various groups are defined herein, and which are useful for treating cancer.

  这里公开了公式(I)、(I)的氮杂吲唑，其中各团簇在本发明中定义，并且用于治疗癌症。
• 신규한 헤테로아릴카르복스아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 ＲＡＧＥ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
  申请人：Seoul National University R&DB Foundation 서울대학교산학협력단(120070509242) Corp. No ▼ 114371-0009224BRN ▼119-82-03684

  公开号：KR101493882B1

  公开（公告）日：2015-02-17

  본 발명은 신규한 헤테로아릴카르복스아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 ＲＡＧＥ 수용체 또는 아세틸콜린에스테라제 활성 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 의한 헤테로아릴카르복스아마이드 유도체 화합물은 RAGE 수용체에 길항작용을 함으로써, 신경세포를 손실하는 베타아밀로이드가 RAGE 수용체와 결합하여 뇌 내로 이동하는 것을 억제하며, 이로 인한 베타아밀로이드의 과다축적으로 형성되는 플라크 생성을 억제 효과가 우수하다. 또한, 기억 기능에 있어서 중요한 화학물질인 아세틸콜린을 분해하는 아세틸콜린에스테라제를 저해하는 효과가 뛰어나므로, RAGE 수용체 또는 아세틸콜린에스테라제 활성 관련 질환인 알츠하이머 질환, 뇌혈관성 치매증, 두부 손상에 의한 치매, 다경색 치매, 알츠하이머 질환과 다경색 치매의 혼합형 또는 알코올성 치매 등을 포함하는 치매, 픽(pick)병, 크루츠-야콥(Creutzfeldt-jakob)병, 저갑상선증, 두부손상에 의한 파킨슨(Parkinson)병, 헌팅턴(Huntington)병 등의 예방 또는 치료에 유용하게 사용될 수 있다.

  This is the Chinese translation of the text you provided: 该发明涉及新型的杂环芳基羰胺衍生物或其药学上可接受的盐、其制备方法以及包含它的ＲＡＧＥ受体或乙酰胆碱酯酶活性相关疾病的预防或治疗药学组合物。根据本发明的杂环芳基羰胺衍生物化合物通过对RAGE受体的拮抗作用，抑制与RAGE受体结合并进入大脑的β-淀粉样蛋白导致神经细胞丧失，从而优越地抑制由此导致的β-淀粉样蛋白过度积累形成斑块的效果。此外，由于其出色的抑制分解乙酰胆碱这一对记忆功能至关重要的化学物质的乙酰胆碱酯酶的作用，因此，RAGE受体或乙酰胆碱酯酶活性相关疾病如阿尔茨海默病、脑血管性痴呆症、脑损伤所致痴呆、多发性硬化症痴呆、阿尔茨海默病和多发性硬化症痴呆的混合型或酒精性痴呆等包括痴呆、皮克病、克罗伊茨-雅各布病、甲状腺功能减退症、脑损伤所致帕金森病、亨廷顿病等的预防或治疗可以得到有效应用。